Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitor-based immunotherapy

Prostate cancer is usually considered as immune "cold" tumor with poor immunogenic response and low density of tumor-infiltrating immune cells, highlighting the need to explore clinically actionable strategies to sensitize prostate cancer to immunotherapy. In this study, we investigated wh...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Theranostics 2022-01, Vol.12 (11), p.4965-4979
Hauptverfasser:	Ma, Zehua, Zhang, Weiwei, Dong, Baijun, Xin, Zhixiang, Ji, Yiyi, Su, Ruopeng, Shen, Kai, Pan, Jiahua, Wang, Qi, Xue, Wei
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Breast cancer Cancer therapies Cell division Cell Line, Tumor Chemotherapy Disease Models, Animal Docetaxel - therapeutic use Gene expression Humans Immunologic Factors Immunotherapy Immunotherapy - methods Lymphocytes Male Mice Nucleotidyltransferases Prostate cancer Prostatic Neoplasms - drug therapy Research Paper Retrospective Studies Tumor Microenvironment Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!